Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...

A new comprehensive hereditary cancer solution offers genetic counseling and multigene panels to enhance early detection of ...